SEC Probes KV Pharmaceutical Stock Options

Law360, New York (March 26, 2008, 12:00 AM EDT) -- KV Pharmaceutical Company said Tuesday that its stock option program is under formal investigation by the U.S. Securities and Exchange Commission.

In a filing Tuesday with the SEC, the company said that it has cooperated with the SEC staff, providing copies of a company audit committee report and all documents collected in the course of the committee's review.

Recently, the SEC staff subpoenaed documents — many of which had already been produced — as part of its formal investigation, KV said. The commission also asked for...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.